Replies to post #253494 on Biotech Values

[Fred Kadiddlehopper]

Are the Zepbound and Mounjaro shortfalls due to increased competition or an overall softening of the market? I'd be surprised if it was the latter.

[DewDiligence]

NVO—(-2%)—3Q24 Ozempic/Wegovy combined sales slightly_below_consensus_expectations:

https://www.barrons.com/articles/novo-nordisk-earnings-stock-price-a38122ea

[DewDiligence]

LLY—(-6%)—announces 4Q24 sales miss/2025 guidance:

https://www.prnewswire.com/news-releases/lilly-provides-update-on-2024-revenue-guidance-announces-2025-revenue-guidance-302349776.html

For Q4 2024, Lilly now expects worldwide revenue to be approximately $13.5 billion, representing growth of 45% compared to Q4 2023. This includes approximately $3.5 billion for Mounjaro and $1.9 billion for Zepbound.

… the company's expected [full-year] 2024 revenue is $400 million or about 3%, below the guidance range issued on October 30, 2024…

2025 revenue guidance is $58-61B, +29-36% relative to 2024’s $45B.